News Search Results
Dec 08, 2025, 11:45 ET Huntington Bank Opens First Branches in Charleston and Greenville
said Gary Daniels, community president for Huntington's Greater Greenville market. "With the opening of this branch, we are creating more opportunities to deliver Huntington's people-first, customer-centered approach to this community." Huntington's expansion in the Carolinas is part of the
More news about: Huntington Bank
Dec 04, 2025, 16:48 ET QURE Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm
2025, uniQure issued a press release revealing that the FDA notified the company that data for its AMT-130, an investigational gene therapy for Huntington's disease, did not provide sufficient evidence to support uniQure's Biologics License Application ("BLA") submission. Specifically, uniQure disclosed
More news about: Kessler Topaz Meltzer & Check, LLP
Dec 01, 2025, 16:20 ET Huntington Bancshares Incorporated to Present at the 2025 Goldman Sachs Financial Services Conference
Webcast InformationInterested investors may access the live audio webcast in the investor relations section of Huntington's website (
More news about: Huntington Bancshares Incorporated
Dec 01, 2025, 11:19 ET Cystic Fibrosis Therapeutics Market Set to Reach USD 35.09 Billion by 2033 as Precision CFTR Modulator Therapies Transform Patient Outcomes
& Surgical Care.Huntington's Disease Market Size to Grow from US$456 M in 2024 to US$3.23 B by 2033 - >7.5% CAGR Signals Surge in Therapeutic & R&D Activity.
More news about: DataM Intelligence 4 Market Research LLP
Dec 01, 2025, 10:00 ET Cornerstone Community Development, Winterwood, CVS Health, and Community Organizations Announce the Prichard Centennial Residential Reveal and Next-Phase Preview
Health® (NYSE: CVS) and other community organizations, invites the public and media to a special event celebrating the transformation of one of Huntington's most historic properties. The Prichard Centennial Residential Reveal & Next-Phase Preview will be held on Thursday, December 4, 2025,
More news about: CVS Health
Nov 28, 2025, 11:46 ET QURE Investigation: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm
2025, uniQure issued a press release revealing that the FDA notified the company that data for its AMT-130, an investigational gene therapy for Huntington's disease, did not provide sufficient evidence to support uniQure's Biologics License Application ("BLA") submission. Specifically, uniQure disclosed
More news about: Kessler Topaz Meltzer & Check, LLP
Nov 26, 2025, 11:15 ET PMI U.S. Launches "Thanks for Giving" to Honor Community Service in New York
funds to support various nonprofits across the state, including Autism Speaks, NYC PBA Widows' and Children's Fund, Beyond Support Network, and the Huntington's Disease Society of America.Thanks for Giving is part of PMI U.S.'s pragmatic philanthropy—a better approach to corporate giving built on
More news about: PMI US Corporate Services, Inc.
Nov 22, 2025, 11:40 ET QURE Investigation Notification: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm
2025, uniQure issued a press release revealing that the FDA notified the company that data for its AMT-130, an investigational gene therapy for Huntington's disease, did not provide sufficient evidence to support uniQure's Biologics License Application ("BLA") submission. Specifically, uniQure disclosed
More news about: Kessler Topaz Meltzer & Check, LLP
Nov 20, 2025, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of uniQure N.V. - QURE
Drug Administration (FDA) during a recent pre-Biologics License Application (BLA) meeting regarding AMT-130, an investigational gene therapy for Huntington's disease (HD)." The press release stated that, "based on the discussions at the meeting, uniQure believes that the FDA currently no longer agrees
More news about: Pomerantz LLP
Nov 20, 2025, 09:00 ET ReviR Therapeutics Receives $4.6 Million CIRM Grant to Advance Huntington's Disease Treatment and Announces Key Development Milestone
HTT-PMS1 genetic medicine program, whereby a small molecule selectively reduces the mRNA of two genes implicated in both the cause and progression of Huntington's disease (HD). ReviR's novel VoyageR technology platform and scientific approach signify a potential paradigm shift in the treatment of neurodegenerative
More news about: ReviR Therapeutics
Nov 20, 2025, 08:30 ET Neurocrine Biosciences Announces Publication of Landmark Narrative Review on FDA-Approved VMAT2 Inhibitors Demonstrating Unique Profile of INGREZZA® (valbenazine) Capsules
(tardive dyskinesia). involuntary movements (chorea) of Huntington's disease. INGREZZA or INGREZZA SPRINKLE do not cure the cause of involuntary movements, and do not treat other symptoms of Huntington's disease, such as problems with thinking or emotions.
More news about: Neurocrine Biosciences, Inc.
Nov 17, 2025, 07:03 ET Huntington Bank and Octane Announce One-Stop Financing Solution for the Outdoor Power Equipment Industry
the best tools and equipment for their lives and business," said Rich Porrello, consumer finance director at Huntington. "This collaboration pairs Huntington's deep expertise in lending with Octane's leading technology, allowing our customers to confidently move through their financing experience."
More news about: Octane
Nov 14, 2025, 11:15 ET Huntington Bank to Offer Free Limited Edition Cleveland Browns Flags, Honoring the 40th Anniversary of the Dawg Pound
communities we serve." The flag design features the Dawg Pound XL logo, as well as Huntington's logo as the Official Bank of the Cleveland Browns. "Huntington's decades-long collaboration with the Browns is an exciting opportunity to continue our growth in Northeast
More news about: Huntington Bank
Nov 14, 2025, 04:17 ET uniQure N.V. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - QURE
2025, uniQure issued a press release concerned a pre-Biologics License Application (BLA) meeting with the FDA about AMT-130, its gene therapy for Huntington's disease (HD). According to the Company, it "believes that the FDA currently no longer agrees that data from the Phase I/II studies of AMT-130 in
More news about: DJS Law Group LLP
Nov 13, 2025, 02:23 ET Interim Report for the period July - September 2025: BioArctic
BrainTransporter, and we are getting closer to selecting the final drug candidates. In addition, we have embarked on an exciting new scientific journey within Huntington's disease. Currently, there are no available disease modifying treatments for patients with this devastating disease, only treatments to reduce or
More news about: BioArctic
Nov 13, 2025, 02:19 ET Interim Report for the period July - September 2025: BioArctic
BrainTransporter, and we are getting closer to selecting the final drug candidates. In addition, we have embarked on an exciting new scientific journey within Huntington's disease. Currently, there are no available disease modifying treatments for patients with this devastating disease, only treatments to reduce or
More news about: BioArctic
Nov 11, 2025, 16:01 ET Neurocrine Biosciences to Present at Upcoming Investor Conferences
and neuropsychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds
More news about: Neurocrine Biosciences, Inc.
Nov 11, 2025, 04:23 ET uniQure N.V. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - QURE
2025, uniQure issued a press release concerned a pre-Biologics License Application (BLA) meeting with the FDA about AMT-130, its gene therapy for Huntington's disease (HD). According to the Company, it "believes that the FDA currently no longer agrees that data from the Phase I/II studies of AMT-130 in
More news about: DJS Law Group LLP
Nov 10, 2025, 20:30 ET QURE Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm
2025, uniQure issued a press release revealing that the FDA notified the company that data for its AMT-130, an investigational gene therapy for Huntington's disease, did not provide sufficient evidence to support uniQure's Biologics License Application ("BLA") submission. Specifically, uniQure disclosed
More news about: Kessler Topaz Meltzer & Check, LLP
Nov 10, 2025, 16:05 ET Neurocrine Biosciences Provides Update on Phase 2 Study of NBI-1070770 in Adults with Major Depressive Disorder
and neuropsychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds
More news about: Neurocrine Biosciences, Inc.
Nov 10, 2025, 14:01 ET Investing in the Future of Parkinson's Research and Care Through The Michael J. Fox Foundation's Edmond J. Safra Fellowship in Movement Disorders
Zealand, where he will help patients with access to deep brain stimulation for the first time, and in tandem, will further research into Parkinson's, Huntington's disease and dementia. Isabel Wurster, MD Fellowship Site:
More news about: The Michael J. Fox Foundation for Parkinson's Research
Nov 04, 2025, 16:01 ET PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results
marketing authorization reviews ongoing including in Japan where decision is expected in Q4 2025 FDA meeting for votoplam Huntington's disease program planned for Q4 FDA meeting planned for vatiquinone Friedreich's ataxia program in Q4
More news about: PTC Therapeutics, Inc.
Oct 30, 2025, 07:00 ET NLS Pharmaceutics Expands CNS Pipeline With AEX-6xx Series Developed by Aexon Labs
ADHD and learning disorders with arousal dysregulation Neurodegenerative diseases, including synucleinopathies and Huntington's disease Intellectual Property The
More news about: NLS Pharmaceutics Ltd.
Oct 29, 2025, 17:00 ET Huntington Bancshares Incorporated Decreases Its Prime Rate To 7 Percent
Huntington's rate last changed on September 18, 2025, decreasing from 7.5 percent to 7.25 percent. About Huntington
More news about: Huntington Bancshares Incorporated
Oct 28, 2025, 16:01 ET Neurocrine Biosciences Reports Third Quarter 2025 Financial Results
another record quarter in new patient starts and total prescriptions, further demonstrating continued unmet need within the tardive dyskinesia and Huntington's chorea market. CRENESSITY's strong launch reflects its status as a first-in-class therapy that is changing standard of care treatment for patients
More news about: Neurocrine Biosciences, Inc.